Poster podcasts


Aesthetic

The Beauty Image Assessment Study: Perspectives of US Millennials, Generation X, and Baby Boomers on Aesthetic Treatments

Noëlle Sherber, MD, FAAD

AAD VMX 2020 - Poster session

View
Atopic Dermatitis

Impact of Baricitinib on Patient-Reported Skin Symptoms, Itch, and Quality of Life in Adult Patients With Moderate-to-Severe Atopic Dermatitis and an Inadequate Response to Topical Therapies From Phase 3 Trials, BREEZE-AD1 and BREEZE-AD2

Peter Lio, MD

AAD VMX 2020 - Poster session

View
Atopic Dermatitis

Baricitinib, an oral, reversible Janus Kinase -1 and -2 inhibitor, for atopic dermatitis: Head and neck response across 2 phase 3 studies

Eric L. Simpson, MD, MCR

AAD VMX 2020 - Poster session

View
Dermoscopy

Clinical Experiences of Dermoscopy on Virus, Fungi and Parasites Infectious Skin Diseases

Ran Yuping, MD, PhD

AAD VMX 2020 - Poster session

View
Intractable Pruritus

Intranasal butorphanol as a rescue therapy for the treatment of intractable pruritus

Dr. Shawn G. Kwatra, MD, MPH - Raveena Khanna, BA

AAD VMX 2020 - Poster session

View
Psoriasis

Efficacy and Safety of Mirikizumab in Patients with Moderate-to-Severe Plaque Psoriasis: 104-Week Results from a Randomized Phase 2 Study

Robert Bissonnette, MD, FRCPC

AAD VMX 2020 - Poster session

View
Psoriasis

Ixekizumab Is Superior to Placebo for the Treatment of Nail, Scalp, and Palmoplantar Psoriasis in Pediatric Patients With Moderate-to-Severe Plaque Psoriasis

Amy S Paller, MD

AAD VMX 2020 - Poster session

View
Psoriasis

Impact of Mirikizumab Maintenance Dosing at Week 104 on Health-related Quality of Life in Patients Who Had < PASI90 Response at Week 16: A Phase 2 Study Analysis

Jerry Bagel, MD, MS

AAD VMX 2020 - Poster session

View
Psoriasis

Achieving a PASI50 at 2 weeks was associated with better long-term clinical outcomes and low discontinuation: a subgroup analysis of a phase 3 trial of ixekizumab and etanercept in moderate-to-severe psoriasis

David Rosmarin, MD

AAD VMX 2020 - Poster session

View
Psoriasis

2018 Geographic Variations in the Use of Biologic Therapy for Psoriasis in the CORRONA PsO Registry

Clinton W. Enos, MD

AAD VMX 2020 - Poster session

View
Psoriasis

10-Year Interim Results from the ESPRIT Registry: Real-World Safety, Effectiveness, and Patient-Reported Outcomes of Adalimumab for Moderate-to-Severe Psoriasis

Jashin J Wu, MD

AAD VMX 2020 - Poster session

View
Psoriasis

Sustained Improvements in Itch, Skin Pain, and Health-Related Quality of Life through 5 years of Treatment with Ixekizumab in Patients with Moderate-to-Severe Plaque Psoriasis

Melinda Gooderham, MSc, MD, FRCPC

AAD VMX 2020 - Poster session

View
Psoriatic Arthritis

Comparison of ixekizumab and adalimumab in the treatment of nail psoriasis in psoriatic arthritis patients with moderate-to-severe psoriasis: 24-week results from a multicentre, randomised, open-label, rater-blinded study (SPIRIT-H2H)

Saxon D. Smith, MBChB, MHL, PhD

AAD VMX 2020 - Poster session

View